# Cystatin-C C-guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project

> **NCT02945241** · PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 399 (actual)

## Conditions studied

- Methicillin-resistant Staphylococcus Aureus
- Sepsis
- Critical Illness

## Interventions

- **DRUG:** Vancomycin
- **OTHER:** Cystatin C dosing algorithm
- **OTHER:** Creatine clearance dosing algorithm

## Key facts

- **NCT ID:** NCT02945241
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2015-06
- **Final completion:** 2016-03
- **Target enrollment:** 399 (ACTUAL)
- **Last updated:** 2023-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02945241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02945241, "Cystatin-C C-guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02945241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*